Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oettinger, C. W.
Right arrow Articles by Macon, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oettinger, C. W.
Right arrow Articles by Macon, E. J.

Journal of the American Society of Nephrology, Vol 3, 995-1001, Copyright © 1992 by American Society of Nephrology

REGULAR ARTICLES

The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients

CW Oettinger, JC Oliver and EJ Macon
Emory University School of Medicine, Atlanta, GA.

Alternative phosphate binders, such as CaCO3, have been shown to be effective in the control of phosphate (P) retention in hemodialysis patients (HDP). Additionally, both oral (POC) and iv (IVC) calcitriol are purported to be of benefit in the control of secondary hyperparathyroidism. This investigation was undertaken to determine: (1) the effectiveness of CaCO3 as the sole P binder in combination with low (2.5 mEq/L) Ca dialysate; (2) the effects of discontinuing Al(OH)3 binders on both unstimulated and stimulated Al concentrations; and (3) the comparative parathyroid hormone (PTH) response to both POC and IVC in a large group of hemodialysis patients. One hundred ninety-four HDP completed part 1 of the study where CaCO3 was substituted for Al(OH)3 as the sole P binder for 6 months. A cohort of 49 HDP was given desferoximine (40 mg/kg) initially and 10 months after using CaCO3. In part 2, 54 HDP were given POC and 97 HDP were given IVC in dosages of 0.25 to 0.5 micrograms/day and 1.5 to 6.0 micrograms/wk, respectively, for an additional 6 months. In part 1, Ca and P were not different from baseline values observed with Al(OH)3 therapy. Ionized Ca increased (P < 0.05) and PTH decreased (P < 0.001) during CaCO3 therapy without vitamin D. In part 2, PTH declined 23% with IVC and was unchanged with POC in equivalent dosages (P < 0.05) at 3 months. By 6 months, PTH declined a total of 54% with IVC and was unchanged with POC. Ca, ionized Ca, P, and serum calcitriol were greater (P < 0.05) in the IVC group at 6 months. Serum Al concentrations for the entire 194 HDP fell 65% (P < 0.0001) over 12 months. In the 49 HDP cohort, serum Al fell 43.6% (P < 0.001) and stimulated Al concentrations decreased 68.7% (P < 0.0001) after 10 months. We conclude that: (1) CaCO3 is as effective as Al(OH)3 in controlling P, (2) a small decrease in PTH is observed with CaCO3 alone, (3) serologic evidence of Al excess is virtually eliminated, (4) PTH suppression with IVC is superior to that seen with POC in equivalent doses.


This article has been cited by other articles:


Home page
 NEJMHome page
K. A. Hruska and S. L. Teitelbaum
Renal Osteodystrophy
N. Engl. J. Med., July 20, 1995; 333(3): 166 - 175.
[Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673